Patient Organisations in the Assessment of Cancer Treatments
The European Cancer Patient Coalition has launched an online education (eLearning) module for patient organisations and patient advocates. The module aims to equip our members and broader patient community with knowledge to participate in the Health Technology Assessment (HTA) of cancer treatments.
The module covers a range of information from medicines development process and their examination as part of HTA, why cancer treatments might be reimbursed in some countries but not in others, and how cancer patient organisations can get involved in the HTA. The module also covers the recent legislative developments on HTA at the EU level and the importance of involvement of patient organisations and patient advocates in Health Technology Assessments.
People living with cancer and their carers best understand the need for new therapies and their impact on quality of life. Their unique knowledge, perspectives and experiences are crucial in determining the value of new treatments in the Health Technology Assessment.
Check out the short introductory video below or scroll down to access the module.
To launch the eLearning module, please click "Enter" on the image below.
We have planned more educational activities on Health Technology Assesment in 2019. Please check back frequently to make sure you stay up to date.
What is the state of play on HTA?
Examples from EU Member States - Leaflet
After gathering information from various experts and our members, the European Cancer Patient Coalition has produced a short but comprehensive leaflet summarizing what is the state of play and how patients are involved in the HTA process in Europe. In particular, we compared how health technologies are assessed in Belgium, England, Finland, Germany, Italy, Netherlands, Romania, and Sweden.
If you would like to comment or to contribute to this list, contact us at firstname.lastname@example.org!
The European Cancer Patient Coalition gratefully acknowledges the support of AbbVie, AstraZeneca, Bristol-Myers Squibb, Cancer Drug Development Forum, Eli Lilly and Company, MSD, Novartis, Roche, Takeda, Tesaro.